Pio Therapeutics
Biotechnology company developing targeted cancer immunotherapies that augment endogenous anti-tumour immunity. The organisation is advancing a differentiated, first-in-class agonistic antibody approach to amplify endogenous IL-21 signalling and address limitations of systemic cytokine administration. The team has expertise spanning therapeutic discovery, preclinical development, IND-enabling activities, early clinical development and commercial translation.
Industries
Nr. of Employees
small (1-50)
Pio Therapeutics
Products
Agonistic antibody targeting IL-21 (preclinical candidate)
Differentiated agonistic antibody designed to bind and amplify endogenous IL-21 signalling to enhance anti-tumour immunity while addressing safety and pharmacokinetic limitations of systemic cytokine administration. Intended for combination with standard-of-care immunotherapies.
PIO-001
An agonistic monoclonal antibody to human IL-21 licensed from Monash University, developed to enhance interleukin-21 activity for cancer and viral immunotherapy.
Agonistic antibody targeting IL-21 (preclinical candidate)
Differentiated agonistic antibody designed to bind and amplify endogenous IL-21 signalling to enhance anti-tumour immunity while addressing safety and pharmacokinetic limitations of systemic cytokine administration. Intended for combination with standard-of-care immunotherapies.
PIO-001
An agonistic monoclonal antibody to human IL-21 licensed from Monash University, developed to enhance interleukin-21 activity for cancer and viral immunotherapy.
Services
Collaborative partnerships with investors, academic groups and industry for co-development, licensing and investment in oncology discovery programs.
Collaborative partnerships with investors, academic groups and industry for co-development, licensing and investment in oncology discovery programs.
Expertise Areas
- Immuno-oncology
- Therapeutic antibody development
- Cytokine biology and IL-21 signalling
- Preclinical development and IND enabling
Key Technologies
- Monoclonal antibody engineering
- Cytokine-targeting biologics (IL-21 modulation)
- Human knock-in disease models
- Preclinical IND-enabling study packages
News & Updates
Press release announcing the launch of Pio Therapeutics (Pio Tx), a company formed to develop novel immunotherapies and to expedite development of a first-in-class agonist antibody targeting IL-21.
Press release announcing the launch of Pio Therapeutics (Pio Tx), a company formed to develop novel immunotherapies and to expedite development of a first-in-class agonist antibody targeting IL-21.